Enovis Outperforms Rennova Health in Key Financial Metrics

Enovis shows stronger profitability, lower volatility, and greater institutional backing compared to Rennova Health

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Enovis (NYSE:ENOV) and Rennova Health (OTCMKTS:RNVA) are both small-cap medical companies, but an analysis of their financial performance and other key metrics shows that Enovis is the stronger business overall. Enovis has lower volatility, higher profitability, and greater institutional ownership compared to the more volatile and less profitable Rennova Health.

Why it matters

This comparison highlights the financial health and growth potential of these two medical companies, which can be important information for investors and industry observers tracking the performance of small-cap players in the healthcare sector.

The details

Enovis has a beta of 1.46, indicating its share price is 46% more volatile than the S&P 500, while Rennova Health has a much higher beta of 22.86, meaning its share price is over 2,100% more volatile. In terms of profitability, Enovis has higher net margins, return on equity, and return on assets compared to Rennova Health. Enovis also has higher revenue and earnings than Rennova Health. Additionally, 98.5% of Enovis shares are owned by institutional investors, compared to just 20.2% for Rennova Health, suggesting stronger backing from large financial institutions.

  • The financial data and analysis is current as of March 8, 2026.

The players

Enovis Corporation

A medical technology company that develops clinically differentiated solutions for reconstructive surgery, rehabilitation, pain management, and physical therapy.

Rennova Health, Inc.

A healthcare services provider that owns one operating hospital in Oneida, Tennessee and a rural clinic in Williamsburg, Kentucky.

Got photos? Submit your photos here. ›

The takeaway

This analysis indicates that Enovis is the stronger and more stable medical company compared to Rennova Health, with lower volatility, higher profitability, and greater institutional backing. Investors and industry observers may want to further research Enovis as a potential investment opportunity in the small-cap healthcare space.